ZELDA THERAPEUTICS LIMITED(ZLD)

name changed to Zelira Therapeutics Limited

The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules.

The company is pleased to announce that it has successfully raised the maximum allowed under its prospectus offering. A total of 160,000,000 post-consolidation shares will be issued to new investors at 2.5 cents per share raising the full $4,000,000. The funds raised are to continue with pre-clinical R&D activities, fund human clinical trials and expand the management/ advisory team.

The company issues a second supplementary prospectus intended to be read with the prospectus dated 11 July 2016 and the supplementary prospectus lodged 11 October 2016.

The company lodges its Quarterly Activities Report.

The company lodges its Quarterly Cashflow Report.

The company's meeting will be held at 12.30pm (WST) on 28 November 2016 at CPS Capital Boardroom Level 45, 108 St Georges Terrace Perth WA 6000.

The company advises that the ASX has granted a waiver from listing rule 14.7 to the extent necessary to permit the Company to issue securities, as approved by shareholders at the general meeting held on 25 July 2016. This is purely a technical issue related to the extended timetable and does not affect any material aspect of the transaction.

we understand that on or about this date the company consolidated its shares 1 for 5

The share consolidation has been completed.

On 11 October 2016, the company lodged a supplementary prospectus with the ASIC which extends the offer period by a minimum of one month. Unfortunately, due to technical issues associated with having the company re-admitted to ASX for quotations the company is required to issue the attached supplementary prospectus and extend the offer period until no earlier than the 11 November 2016.

name changed from Gleneagle Gold Limited